Latest Healthcare News

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Cann Group Limited has agreed to fully redeem its outstanding convertible notes with Obsidian Global GP, LLC at 100% of face value, foregoing the usual early redemption premium. This move concludes the convertible securities facility established earlier in the year.

Saluda Medical has obtained FDA approval for its CAP24 surgical paddle lead, a first-of-its-kind device designed for closed-loop spinal cord stimulation, poised to broaden its US market reach and engage new surgical specialties.

CONNEQT Health Limited is offering eligible shareholders a share purchase plan to raise up to $0.5 million at a 24.3% discount, aiming to fund its next growth phase in vascular health technology.

Truscreen Group has issued nearly 150 million new shares at NZ$0.013 each, expanding its share base by 17.4% following a renounceable rights issue. The fully paid shares rank equally with existing stock, lifting total ordinary shares to just over one billion.

Adherium Limited has obtained a USD 1.65 million short-term unsecured loan from its major shareholder, Trudell Medical, to fund immediate working capital needs while pursuing capital structure adjustments.

BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

Talius has landed a $1.15 million contract with Seventh-day Adventist Aged Care (North NSW), doubling its recent Queensland deal and adding over $100,000 in annual recurring revenue.

Alcidion confirms FY26 revenue above $50 million and EBITDA over $5 million, completing the Kyra flow products acquisition from Telstra Health to expand its patient flow solutions in ANZ and the UK.